You are here

Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy

Last updated on November 14, 2019

FOR MORE INFORMATION
Study Location
Consultorios Especializados en Investigaciones Medicas
Capital Federal, Buenos Aires, C1425EKF Argentina
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-69 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of Rheumatoid Arthritis (RA)

- Currently receiving a suboptimal response to a stable dose of methotrexate for
treatment of Rheumatoid Arthritis (RA)

- Active Rheumatoid Arthritis (RA) at time of screening and baseline

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Previous or current treatment with etanercept, other tumor necrosis factor-alpha
inhibitors, or other biologic agents

- Concurrent treatment with a Disease Modifying Antirheumatic Drug (DMARD), other than
methotrexate, at screening

- Receipt of any Disease Modifying Antirheumatic Drug (DMARD), other than methotrexate,
within 3 months before screening

NCT00848354
Pfizer
Completed
Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Rheumatoid Arthritis
NCT03981900
All Genders
18+
Years
Multiple Sites
Rheumatoid Arthritis, Psoriatic Arthritis
NCT02984020
All Genders
19+
Years
Multiple Sites
Descriptive Information
Brief Title  ICMJE Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy
Official Title  ICMJE A Randomized, Open-label Study In The Latin America Region Comparing The Safety And Efficacy Of Etanercept With Conventional Dmard Therapy In Subjects With Rheumatoid Arthritis.
Brief SummaryThe purpose of this 2 phased, open-label study is to compare the safety and efficacy of etanercept with conventional Disease Modifying Antirheumatic Drug (DMARD) therapy in Latin American subjects with moderate to severe rheumatoid arthritis over 128 weeks. Phase 1 is a randomized 24 week treatment period; Phase 2 is an optional open-label 104 week period that allows the investigator to choose continuation with the phase I treatment or the addition, discontinuation or titration of other DMARD therapy already being utilized for the study.
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Rheumatoid Arthritis
Intervention  ICMJE
  • Biological: Phase 1: Etanercept
    Phase 1: prefilled syringe 50mg/ml, administered once weekly for study weeks 0 - 24
    Other Name: Enbrel
  • Drug: Phase 1: Methotrexate
    Phase 1: oral tablet, 2.5mg, dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
  • Drug: Phase 2: Optional ETN, SSZ, HCQ, MTX

    Phase 2: All therapies are optional and may include any combination of the following: ETN, SSZ, HCQ, MTX Phase 2: Optional ETN: prefilled syringe 50mg/ml, dose variable after study week 24 to week 128.

    Phase 2: Optional SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations after study week 24 to week 128.

    Phase 2: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations after study week 24 to week 128.

    Phase 2: MTX: oral tablet, 2.5mg dose variable after week 24 to week 128.

  • Drug: Phase 1: Methotrexate
    Phase 1: oral tablet, 2.5mg dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
  • Drug: Phase 1: Conventiaonal DMARD
    Phase 1: SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations. OR Phase 1: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations.
Study Arms  ICMJE
  • Experimental: Phase 1 Etanercept + methotrexate
    Phase 1: Etanercept + methotrexate
    Interventions:
    • Biological: Phase 1: Etanercept
    • Drug: Phase 1: Methotrexate
    • Drug: Phase 2: Optional ETN, SSZ, HCQ, MTX
  • Active Comparator: Phase 1 Conventional DMARD (SSZ or HCQ) + MTX
    Phase 1: Sulfasalazine (SSZ) + methotrexate (MTX) OR Phase 1: Hydrocholoquine (HCQ) + methotrexate
    Interventions:
    • Drug: Phase 1: Methotrexate
    • Drug: Phase 1: Conventiaonal DMARD
Publications *


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 8, 2013)
429
Original Estimated Enrollment  ICMJE
 (submitted: February 19, 2009)
414
Actual Study Completion Date  ICMJE April 2013
Actual Primary Completion DateApril 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of Rheumatoid Arthritis (RA)
  • Currently receiving a suboptimal response to a stable dose of methotrexate for treatment of Rheumatoid Arthritis (RA)
  • Active Rheumatoid Arthritis (RA) at time of screening and baseline

Exclusion Criteria:

  • Previous or current treatment with etanercept, other tumor necrosis factor-alpha inhibitors, or other biologic agents
  • Concurrent treatment with a Disease Modifying Antirheumatic Drug (DMARD), other than methotrexate, at screening
  • Receipt of any Disease Modifying Antirheumatic Drug (DMARD), other than methotrexate, within 3 months before screening
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 69 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Chile,   Colombia,   Mexico,   Panama
Removed Location CountriesBrazil,   Ecuador,   Spain,   Venezuela
 
Administrative Information
NCT Number  ICMJE NCT00848354
Other Study ID Numbers  ICMJE 0881A1-4532
B1801004 ( Other Identifier: Alias Study Number )
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyPfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Amgen
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateDecember 2015

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now